Compare OOMA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | AKBA |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.2M | 380.4M |
| IPO Year | 2015 | 2014 |
| Metric | OOMA | AKBA |
|---|---|---|
| Price | $14.41 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $18.77 | $5.25 |
| AVG Volume (30 Days) | 232.2K | ★ 2.3M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | 93.94 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $114,490,000.00 | N/A |
| Revenue This Year | $20.35 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | $63.65 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $1.14 |
| 52 Week High | $15.15 | $4.08 |
| Indicator | OOMA | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 58.68 | 54.02 |
| Support Level | $10.95 | $1.30 |
| Resistance Level | $14.83 | $1.55 |
| Average True Range (ATR) | 0.50 | 0.06 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 56.32 | 67.65 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.